Aktuelle Studiensituation der neuen Antikoagulantien – Thromboembolische Erkrankungen

Eine effektive und sichere Antikoagulation ist ein wesentlicher Bestandteil der Therapie thromboembolischer Erkrankungen. Oral verabreichte Vitamin-K-Antagonisten (VKA) waren bislang die Standardpräparate für diese Behandlung. Die neuen direkten Antagonisten der Gerinnungsfaktoren FXa (Rivaroxaban und Apixaban) und Thrombin (Dabigatran) haben sich in Studien als effektiv und sicher für die Indikationen Thromboseprophylaxe, Thrombosetherapie (Rivaroxaban) und Embolieprophylaxe bei Vorhofflimmern erwiesen. Ihr Einzug in die klinische Praxis wird ein neues Zeitalter der Antikoagulation einläuten.

Safe and effective anticoagulation is a therapeutic cornerstone of thromboembolic diseases. Until recently oral vitamin K antagonists were the standard drugs for this indication. The new oral antagonists of the coagulation factors Xa (apixaban, rivaroxaban) or thrombin (dabigatran) demonstrated a safe and effective profile in large clinical trial in the fields of prevention of deep vein thrombosis, therapy of deep vein thrombosis (rivaroxaban) and prevention of stroke or systemic embolism in patients with atrial fibrillation. Their entry into clinical practice will initiate a new age of anticoagulation.

Key words

new anticoagulants - atrial fibrillation - Apixaban - Dabigatran - Rivaroxaban

• Literatur

• 1 Eriksson BI et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956
• 2 Schulman S et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352
• 3 Connolly SJ et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
• 4 Connolly SJ et al. Newly identified events in the RE-LY trial. N Engl J Med 1875-1876
• 5 Diener HC et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157-1163
• 6 Turpie AG et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-453
• 7 Bauersachs R et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510
• 8 Patel MR et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011;
• 9 Fox KA et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-2394
• 10 Lassen MR et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-2498
• 11 Goldhaber SZ et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365: 2167-2177
• 12 Granger CB et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med online publication 28. August 2011;
• 13 Oldgren J et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781-2789
• 14 Alexander JH et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708
• 15 Mega JL et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19